Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Saved in:
| Title: | Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. |
|---|---|
| Authors: | Micke P; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O |
| Source: | International journal of cancer [Int J Cancer] 2014 Nov 01; Vol. 135 (9), pp. 2206-14. Date of Electronic Publication: 2014 Apr 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
